BOOK HERE OR WALK IN

Regular flu shots 6months – 64 years IN STOCK

High dose 65+ flu shots IN STOCK

For KMC patients and general public (12+ years of age) to book.

BOOK HERE

OUT OF STOCK until next covid booster becomes available late Fall 2026

Covid Vaccine: PFIZER

***RSV is publicly funded to all individuals aged 75 and older***

75+ AREXVY® Vaccine: Available now, IN STOCK
BOOK HERE

HIGH RISK 60-74, AREXVY® Vaccine: IN STOCK
BOOK HERE
Eligibility Criteria:

• lives in long term care/retirement residences

• on hemo/ or peritoneal dialysis

• patient with glomerulonephritis (GN) and is moderately-severely immunocompromised

• organ/stem cell transplant recipients

• patients experiencing homelessness

• identify as First Nations, Inuit, or Metis

Adults who previously received a dose of RSV vaccine do not need another dose this season.

Beyfortus (weight 5kg+) IN STOCK
BOOK HERE

Beyfortus (weight under 5kg) Limited doses OUT OF STOCK
BOOK HERE

Infants and high-risk children

• National Advisory Committee on Immunization (NACI) updated RSV guidance for infants and children

  In April 2026, NACI removed its preferential recommendation for monoclonal antibodies (Beyfortus) for infant RSV prevention. Beyfortus and Abrysvo are both effective options for preventing severe RSV in infants, with emerging evidence suggesting similar protection. Beyfortus remains available to eligible infants and high-risk children, supported by high uptake and reduced hospitalizations. Abrysvo during pregnancy is an effective alternative for infant protection. Abrysvo and Beyfortus are not routinely recommended together, except in specific cases (e.g., high-risk infants born to vaccinated mothers). Product choice should be discussed with a health care provider.

  For more information, please see: Updated guidance to protect infants and children from respiratory syncytial virus (RSV) disease: use of monoclonal antibodies (nirsevimab and clesrovimab) and the RSVpreF vaccine

• Beyfortus eligibility as per Ministry eligibility criteria:

  • Infants born April 1, 2026 or after and less than 8 months of age at the time of immunization.

  • Children up to 24 months of age who remain vulnerable from severe RSV disease through their second RSV season, following discussion with a health care provider, which includes children with:

    • Chronic lung disease (CLD), including bronchopulmonary dysplasia (BPD), defined by need for ongoing respiratory support and supplemental oxygen therapy at 36 weeks postmenstrual age (gestational age at birth plus chronological age) or discharged home, if earlier

    • Hemodynamically significant cyanotic or acyanotic congenital heart disease (CHD) defined as infants requiring corrective surgery or are on cardiac medication for congestive heart failure or diagnosed with moderate to severe pulmonary hypertension

    • Severe immunodeficiency

    • Down Syndrome / Trisomy 21

    • Cystic fibrosis with recurrent pulmonary exacerbations requiring hospitalization, deteriorating pulmonary function and/or severe growth delay

    • Neuromuscular disease impairing clearing of respiratory secretions

    • Severe congenital airway anomalies impairing the clearing of respiratory secretions

Vaccination in pregnancy

Pregnant individuals are eligible to receive a single dose of Abrysvo. Abrysvo is the only RSV vaccine currently indicated in pregnancy. Doses in subsequent pregnancies are not currently recommended.

Eligibility: 28 to 36 weeks gestational age who will deliver during the RSV season.

Health Canada authorization is for use at 32-36 weeks of pregnancy. NACI recommends administration between 28-36 weeks; administration before 32 weeks is off-label and at the discretion of the health care provider based on clinical judgment.

BOOK HERE, or get during your next prenatal visit IN STOCK